Search clinical trials for: sitagliptin and acarbose

Total 271196 results

Evidem Consultores SL
Boehringer Ingelheim; Merck Serono International SA; European Commission

Unknown

Prevention of Microvascular Complications in Prediabetes e-PREDICE Study (ePREDICE)

PreDiabetes

Spain
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

Renal Insufficiency
Boehringer Ingelheim

Completed

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Novartis Pharmaceuticals

Withdrawn

Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

Type 2 Diabetes Mellitus
GlaxoSmithKline

Completed

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes (SGA112534)

Diabetes Mellitus, Type 2

Germany, United States, France, United Kingdom
AstraZeneca

Completed

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin

United States
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

Obesity

United States
Hospital de Especialidades, Centro Medico Nacional...
National Polytechnic Institute, Mexico

Completed

SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H) (SITAGLAR-H)

Type 2 Diabetes

Mexico
Getz Pharma

Completed

Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients (DQOL)

Quality of Life | Type 2 Diabetes | Metformin+Sitagliptin

Pakistan
University of Leicester
Novo Nordisk A/S; University Hospitals, Leicester

Completed

Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) (LYDIA)

Cardiovascular Disease | Type 2 Diabetes Mellitus

United Kingdom
Garvan Institute of Medical Research

Completed

Effects of Glutamine on GLP-1 and Insulin Secretion in Man

Type 2 Diabetes

Australia
Johns Hopkins University
Merck Sharp & Dohme LLC

Terminated

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

Glucose Homeostasis

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

Type 2 Diabetes
Tehran University of Medical Sciences

Completed

Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

Uncontrolled Type 2 Diabetes Mellitus

Iran, Islamic Republic of
Novo Nordisk A/S

Completed

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Puerto Rico, United Kingdom, Ireland, Germany, Slovenia, Canada, France, Italy, Spain, Netherlands, Slovakia, Romania, Former Serbia and Montenegro
Royal Adelaide Hospital
Merck Sharp & Dohme LLC

Completed

Effects of Sitagliptin on Gastric Emptying in Healthy Subjects

Diabetes Mellitus | Gastroparesis

Australia
Merck Sharp & Dohme LLC

Completed

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Renal Insufficiency | Hemodialysis
Seoul National University Bundang Hospital

Completed

Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination (COSMETIC)

Diabetes

Korea, Republic of
Cadila Pharnmaceuticals
New Millennium Indian Technology Leadership Initiative (NMITLI) program of...

Completed

Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus

Uncontrolled Type 2 Diabetes Mellitus

India
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

Diabetes Mellitus, Type 2
Takeda

Completed

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Mexico
GlaxoSmithKline

Completed

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany, Mexico, Peru, Russian Federation, United Kingdom, Philippines, South Africa, Spain, Hong Kong, Albania
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

Type 2 Diabetes Mellitus
Seoul National University Hospital

Unknown

Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients

Type 2 Diabetes | Endothelial Function | Gemigliptin | Acarbose

Korea, Republic of
The Hospital for Sick Children

Terminated

A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic Fatty Liver Disease

Canada
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Terminated

Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity

Cardiovascular Disease | Insulin Resistance | Pediatric Obesity | Impaired Glucose Tolerance

United States
University of Pennsylvania

Recruiting

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

Heart Failure | Type2 Diabetes | Genetics Disease

United States
University Health Network, Toronto
Novo Nordisk A/S

Enrolling by invitation

Semaglutide vs Sitagliptin

Diabetes Mellitus | NAFLD | NASH - Nonalcoholic Steatohepatitis | Liver Transplant; Complications

Canada
Li Bo

Completed

Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

Type 2 Diabetes Mellitus | Atherosclerosis

China
Merck Sharp & Dohme LLC

Completed

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

Type 2 Diabetes Mellitus (T2DM)
Merck Sharp & Dohme LLC

Completed

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Type 2 Diabetes
University Medical Centre Ljubljana

Completed

Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

PCOS
Takeda

Terminated

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Glycemic Control

United States, Bulgaria, Malaysia, Korea, Republic of, Australia, Czech Republic, Hungary, Thailand, Italy, Slovakia, Croatia
Merck Sharp & Dohme LLC

Completed

MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)

Type 2 Diabetes Mellitus
University Hospital, Gentofte, Copenhagen
Merck Sharp & Dohme LLC

Completed

Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes

Type 2 Diabetes

Denmark
Instituto Nacional de Ciencias Medicas y Nutricion...
Merck Sharp & Dohme LLC

Completed

Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism

Reactive Hypoglycemia

Mexico
Boehringer Ingelheim

Completed

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2

Belgium, Canada, France, India, Italy, Korea, Republic of, Malaysia, Netherlands, Spain
Merck Sharp & Dohme LLC

Completed

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Diabetes Mellitus | Type 2 Diabetes
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

Hypertension | Diabetes

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Diabetes Mellitus, Type 2

Bangladesh, Belgium, Canada, China, Germany, Guatemala, Hong Kong, India, Lebanon, Mexico, Peru, Philippines, Spain, Taiwan
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers

Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin

Diabetes Mellitus, Type 2

Spain, United Kingdom, United States, France
Merck Sharp & Dohme LLC

Completed

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Sanofi

Completed

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients (EASIE)

Diabetes Mellitus, Type 2

United States, Brazil, Netherlands, Portugal, Spain, Turkey, India, Austria, Egypt, Greece, Israel, Mexico, United Kingdom, Korea, Republic of, Hong Kong, Colombia, Lebanon
Shahid Beheshti University of Medical Sciences
Isfahan University of Medical Sciences

Completed

Iranian Intensive Care Unit (ICU) Glutamine Study

Trauma Patients in ICU

Iran, Islamic Republic of
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Type 2 Diabetes Mellitus

Search clinical trials for: sitagliptin and acarbose

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations